Ocular surface toxicities associated with modern anticancer therapies
Cancer treatments have recently shifted from broad-spectrum cytotoxic therapies to more focused treatments, maximizing anti-cancerous activity while reducing toxicity to healthy cells. These modern anticancer therapies (MATs) encompass a wide range of innovative molecules that mainly include immune checkpoint inhibitors (ICIs) and targeted anticancer therapies (TATs), comprising antibody drug conjugates (ADCs) and inhibitors of signal transduction (IST). Some MATs are associated with ocular surface (OS) adverse events (AEs) that can cause severe discomfort and even lead to loss of vision.
Source: Survey of Ophthalmology - Category: Opthalmology Authors: Rafael Boucher, Oscar Haigh, Emmanuel Barreau, St éphane Champiat, Olivier Lambotte, Clovis Adam, Marc Labetoulle, Antoine Rousseau Tags: Review article Source Type: research